Visual acuity and quantitative perimetry (Octopus Program 32) testing was performed in the acute (<30 days after onset) and convalescent (>3 months after onset) phases of disease in 27 patients with untreated NAION. Initial group mean acuity and sensitivity loss were compared to final values using the t test. Proportions of patients demonstrating a change of >2 lines acuity or >2 dB mean sensitivity were calculated. Patients were classified as either "progressive" (« = 6) or "stable" (n = 21) for purposes of additional subgroup analysis. There was no significant change in group mean visual acuity or field over time. Overall, significant worsening occurred in 11.1% for visual acuity and 22.2% for visual field; improvement occurred in 23.8% for acuity and 24.0% for field. Of 21 "stable" patients, none worsened for acuity and 4.7% showed late worsening of field; 31.3% showed significant improvement for acuity and 31.6% for field.
In nonarteritic anterior ischemic optic neuropathy (NAION), the degree of visual loss has been characterized as "monotonously stable" (1) . There is, however, a well-documented subgroup of patients in which initial visual loss is followed by gradual or episodic deterioration over several weeks ("progressive" NAION) (2) (3) (4) . Additionally, retrospective analysis of visual acuity data in a large series of untreated patients (preliminary abstract) (5) has suggested a significant incidence of improvement without therapy; spontaneous recovery of acuity has similarly been noted in isolated cases of the progressive form (6, 7) . Visual acuity is, however, a limited measure of optic nerve function, and similar detailed analysis of visual field data has not been performed. We present sequential quantitative perimetry and visual acuity data in 27 cases of untreated NAION.
PATIENTS AND METHODS
Visual acuity and quantitative perimetry (Octopus Program 32) testing were performed in 22 cases of acute NAION seen at the Jules Stein Eye Institute from 1989 to 1992. All patients were age 45 or older, with recent (within 30 days) onset of monocular visual loss, and the presence of an afferent pupillary defect, optic disc swelling, and visual field loss consistent with NAION. No patients had evidence of prior visual loss in the same eye, systemic symptoms suggestive of vasculitis (including temporal arteritis) or demyelinating disease, or elevation of Westergren sedimentation rate greater than 40 mm/h. Two patients received oral prednisone, Patient 22 at 60 mg per day for 4 days and Patient 25 tapering from 80 mg per day to no therapy in 8 days; no other patients received treatment. Follow-up acuity and perimetry testing by the same technique were performed at least 3 months after initial evaluation. Retrospective re-view of 140 cases of NAION seen at the same institute from 1983 to 1994 revealed five additional untreated patients who met the same criteria.
Of the total 27 patients included, 22 were male and 5 female, with mean age 64.7 years (range: 48 to 85). Initial visual acuity and perimetry testing was performed from 3 to 26 days (mean 11.9 days) after onset of symptoms; final testing was accomplished from three to 76 months (mean 12.6 years) after onset.
Initial group mean values for visual acuity and mean sensitivity loss were compared to final group mean values using the Student's f test. In order to estimate the effect of long-term fluctuation and learning on perimetry data in this patient group, the change in group mean sensitivity loss in fellow eyes over time was calculated (-1.00 dB). Based on this value, a 2-dB alteration in mean sensitivity loss was used as the criterion for definite change. The proportions of patients demonstrating a change of >2 lines Snellen acuity of >2 dB mean sensitivity loss were calculated. Patients sustaining additional visual loss (by either acuity or field criteria) within 2 months after initial symptom onset were classified as progressive NAION, with the remaining patients considered stable NAION; similar calculations for visual acuity and mean sensitivity loss were performed within each of these subgroups.
RESULTS
Patient profiles, visual acuity, and visual field data are summarized in Table 1 .
Change in overall group mean acuity from initial to final testing was +0.37 lines and in mean sensitivity loss +0.57 dB, neither statistically significant at the P < .05 level. Three of 27 (11.1%) demonstrated significant (>2 line) decrease in Snellen acuity, with 6 of 27 (22.2%) showing significant (>2 dB) increase in mean sensitivity loss. Five of 21 (23.8%) increased in acuity and 6 of 25 (24.0%) decreased in mean sensitivity loss (six patients with initial acuity of 20/20 and two with initial mean sensitivity loss of less than 2 dB were excluded because improvement from these levels was limited).
Six patients (22.2%) were considered progressive (Patients 22 to 27); three suffered a second discrete episode of visual loss within 1 month of 01  02  03  04  05  06  07  08  09  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27   Age   58  63  70  68  62  85  61  67  52  69  67  64  62  48  56  65  76  60  63  69  69  48  67  74  68  79 57 T, time: Time 1 refers to interval from symptom onset to initial testing; Time 2 refers to interval from symptom onset to final testing.
VA, visual acuity. VF, visual field: VF1 and VF2 refer to initial and final mean sensitivity loss, in decibels; VF1A and VF2A refer to initial and final mean sensitivity loss, in decibels, in contralateral eye.
initial symptoms, with three showing gradual or poorly defined further loss during the month following initial symptoms. None showed significant worsening or improvement after the progressive phase of visual loss.
Of the 21 patients considered stable, change in group mean acuity from initial to final testing was + 1.66 Snellen lines and in mean sensitivity loss was -1.34 dB. None of the 21 significantly decreased in acuity, while one of 21 (5.7%) showed a late increase in mean sensitivity loss (probable "recurrent" NAION). Five of 16 (31.3%) demonstrated >2 line increase in acuity and six of 19 (31.6%) showed >2 dB decrease in mean sensitivity loss.
DISCUSSION
The clinical course of untreated NAION has been incompletely studied. The majority of reports concerning natural history describe visual acuity, a parameter that may not accurately represent overall optic nerve function. In all studies, the majority of patients maintained stable acuity, with figures for deterioration by at least 2 lines Snellen acuity ranging from 0 to 24% and for spontaneous improvement ranging from 0 to 50% (1, 5, (8) (9) (10) (11) (12) (13) (14) (15) (16) . In a recent preliminary abstract, Movsas and colleagues (5) reported deterioration in 44 of 242 patients (18%) and improvement in 53 of 242 (21.9%). Isolated cases of spontaneous improvement in patients who had previously deteriorated (progressive NAION) have recently been documented (6, 7) .
Visual field data has occasionally been provided, but quantitative analysis has been limited. Hayreh and Podhajsky (11) reported qualitative deterioration on Goldmann perimetry in 1 of 11 patients (9.1%) and improvement in 5 of 11 (45.5%). Boghen and Glaser (1) noted deterioration of visual field in 11 of 37 patients (29.7%) and Repka and associates (12) 3/83 (3.6%); neither described significant improvement. There has been no detailed study of quantitative static perimetry in untreated NAION.
Our data corroborate prior reports of deterioration in both visual acuity (11.1% and visual field (22.2%) and confirm a subgroup of patients who demonstrate spontaneous improvement in both acuity (23.8%) and fields (24.0%) over time. We did not document spontaneous improvement in any case of progressive NAION. We chose 2 dB as the minimum criterion for visual field change in order to retain sensitivity for detection of change while taking into account both learning effect and normal long-term fluctuation (mean increase of 1.00 dB in contralateral eyes). If the criterion is modified by requiring a change of 2 dB greater than the change in the corresponding fellow eye, the value for deterioration increases to 37.0% (10/27 cases) and for spontaneous improvement decreases to 12.0% (3/25 cases).
Quantitative perimetry is a better measure of overall optic nerve damage than visual acuity, which may vary widely with minor changes in central function. Our data provide strong evidence in support of the significant incidence of spontaneous recovery in nonprogressive NAION that has been suggested by previous reports of acuity and qualitative field improvement. Enthusiasm generated by improved optic nerve function after optic nerve sheath decompression for nonprogressive NAION must be tempered by the knowledge that significant numbers may improve spontaneously (17) . The lower rate of such improvement in untreated progressive cases makes therapeutic success in this form of the disease, (18) as originally proposed by Sergott and associates (14) , more credible. The controlled data generated by the Ischemic Optic Neuropathy Decompression Trial (IONDT) may help to clarify these issues.
